Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | FDPS | P14324 | 1/20 | 0.46 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21317693 | 0.89 | POLB (0.47) | POLBHPGDFDPSEGLN3CYP19A1 | |
| SCHEMBL28168250 | 0.87 | POLB (0.46) | POLBHPGDFDPSEGLN3CYP19A1 | |
| SCHEMBL13108577 | 0.87 | POLB (0.46) | POLBHPGDFDPSEGLN3CYP19A1 | |
| SCHEMBL12900040 | 0.87 | POLB (0.46) | POLBHPGDFDPSEGLN3CYP19A1 | |
| SCHEMBL6898380 | 0.86 | — | — | |
| SCHEMBL10771116 | 0.86 | POLB (0.44) | POLBHPGDFDPSEGLN3CYP19A1 | |
| SCHEMBL5606579 | 0.84 | POLB (0.43) | POLBHPGDFDPSEGLN3CYP19A1 | |
| SCHEMBL18538766 | 0.82 | POLB (0.43) | POLBHPGDFDPSEGLN3CYP19A1 | |
| SCHEMBL16433861 | 0.82 | POLB (0.52) | POLBHPGDEGLN3CYP19A1 | |
| SCHEMBL20516158 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0618198-B1 | Process for the preparation of derivatives of 1-(1,2,4-triazol-1-yl)-propan-2-ol | TEVA PHARMA (IL) | 2000-05-03 | — | — | EP | claimed |
| US-5484936-A | Processes for the preparation of 1,3-bis(1,2,4-triazol-1-yl)-propan-2-ol derivatives | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1996-01-16 | — | — | US | claimed |
| EP-0618198-A1 | Process for the preparation of 1,3-bis (1,2,4-triazol-1-yl)-propan-2-ol derivatives | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1994-10-05 | — | — | EP | claimed |
| JP-6340637-A | — | — | None | — | — | JP | disclosed |
| JP-6340637-A | — | — | None | — | — | JP | disclosed |
| US-8753875-B2 | Compositions and means for diagnosing microbial infections | STATENS SERUM INSTITUT (DK) | 2014-06-17 | — | — | US | disclosed |
| US-20090068696-A1 | COMPOSITIONS AND MEANS FOR DIAGNOSING MICROBIAL INFECTIONS | STATENS SERUM INSTITUT | 2009-03-12 | — | — | US | disclosed |
| EP-0618198-B1 | Process for the preparation of derivatives of 1-(1,2,4-triazol-1-yl)-propan-2-ol | TEVA PHARMA (IL) | 2000-05-03 | — | — | EP | disclosed |
| EP-0831815-A1 | USE OF BIS-1,2,4-TRIAZOLES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CANCERS | THE PROCTER & GAMBLE COMPANY (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040120-A1 | USE OF BIS-1,2,4-TRIAZOLES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CANCERS | THE PROCTER & GAMBLE COMPANY (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5484936-A | Processes for the preparation of 1,3-bis(1,2,4-triazol-1-yl)-propan-2-ol derivatives | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1996-01-16 | — | — | US | disclosed |
| US-5484936-A | Processes for the preparation of 1,3-bis(1,2,4-triazol-1-yl)-propan-2-ol derivatives | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1996-01-16 | — | — | US | disclosed |
| US-5484936-A | Processes for the preparation of 1,3-bis(1,2,4-triazol-1-yl)-propan-2-ol derivatives | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1996-01-16 | — | — | US | disclosed |
| JP-H06340637-A | PREPARATION OF 1,3-BIS(1,2,4-TRIAZOL-1-YL)-PROPAN-2-OL DERIVATIVE | TEVA PHARMACEUT IND LTD | 1994-12-13 | — | — | JP | disclosed |
| JP-H06340637-A | PREPARATION OF 1,3-BIS(1,2,4-TRIAZOL-1-YL)-PROPAN-2-OL DERIVATIVE | TEVA PHARMACEUT IND LTD | 1994-12-13 | — | — | JP | disclosed |
| EP-0618198-A1 | Process for the preparation of 1,3-bis (1,2,4-triazol-1-yl)-propan-2-ol derivatives | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1994-10-05 | — | — | EP | disclosed |
| EP-0618198-A1 | Process for the preparation of 1,3-bis (1,2,4-triazol-1-yl)-propan-2-ol derivatives | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1994-10-05 | — | — | EP | disclosed |
| EP-0618198-A1 | Process for the preparation of 1,3-bis (1,2,4-triazol-1-yl)-propan-2-ol derivatives | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1994-10-05 | — | — | EP | disclosed |
| US-4618616-A | MAMMALS AND PLANTS; 1,2,4-TRIAZOLE DI-SUBSTITUTED | PFIZER INC. (US) | 1986-10-21 | — | — | US | disclosed |
| US-4510148-A | 2-Heterocyclic-1,3-bis(1H-1,2,4-triazol-1-yl)-propan-2-ols as antifungal agents | PFIZER INC. (US) | 1985-04-09 | — | — | US | disclosed |